|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on August 8, 2002; DOI 10.1182/blood-2002-06-1683.
NEOPLASIA
From the Division of Hematology/Oncology, Department of
Medicine, University of California, San Diego for the CLL Research
Consortium, San Diego, CA; Long Island Jewish Hospital, New
York, NY; and the Department of Medicine, Howard Hughes Medical
Institute, University of California, San Francisco.
We examined isolated leukemia B cells of patients with chronic
lymphocytic leukemia (CLL) for expression of zeta-associated protein 70 (ZAP-70). CLL B cells that have nonmutated
immunoglobulin variable region genes (V genes) expressed levels
of ZAP-70 protein that were comparable to those expressed by normal
blood T cells. In contrast, CLL B cells that had mutated immunoglobulin
variable V genes, or that had low-level expression of CD38,
generally did not express detectable amounts of ZAP-70 protein.
Leukemia cells from identical twins with CLL were found discordant for
expression of ZAP-70, suggesting that B-cell expression of ZAP-70 is
not genetically predetermined. Ligation of the B-cell receptor (BCR) complex on CLL cells that expressed ZAP-70 induced significantly greater tyrosine phosphorylation of cytosolic proteins, including p72Syk, than did similar stimulation of CLL cells that did
not express ZAP-70. Also, exceptional cases of CLL cells that expressed
mutated immunoglobulin V genes and ZAP-70 also experienced higher
levels tyrosine phosphorylation of such cytosolic proteins following BCR ligation. Following BCR ligation, ZAP-70 underwent tyrosine phosphorylation and became associated with surface immunoglobulin and
CD79b, arguing for the involvement of ZAP-70 in BCR
signaling. These data indicate that expression of ZAP-70 is associated
with enhanced signal transduction via the BCR complex, which may
contribute to the more aggressive clinical course associated with CLL
cells that express nonmutated immunoglobulin receptors.
(Blood. 2002;100:4609-4614) The leukemia B cells of patients with chronic
lymphocytic leukemia (CLL) can be classified into 1 of at least 2 major
subgroups on the basis of the mutational status of their expressed
immunoglobulin variable (V) genes.1,2 Patients with CLL
cells that express nonmutated genes tend to have a relatively
aggressive clinical course when compared with patients who have CLL
cells that express immunoglobulin V genes with somatic
mutations.2-4 Moreover, patients with leukemia cells that
express nonmutated immunoglobulin V genes are generally more likely to
have CLL cells with atypical morphology, advanced clinical stage, and
progressive disease.3 However, the mechanism accounting
for the differences in clinical behavior of these 2 types of CLL
is unknown.
Recent studies on the gene expression profiles of isolated CLL B cells
have revealed a set of genes that is differentially expressed
in these 2 subgroups.5,6 CLL cells from different patients share common expression levels of many genes and have a gene
expression profile distinct from that of other B-cell malignancies or
normal B cells. However, CLL cells that express nonmutated immunoglobulin V genes can be distinguished from leukemia cells that
have mutated immunoglobulin V genes through their differential expression of a small subset of genes. One of these genes encodes zeta-associated protein 70 (ZAP-70), a 70-kDa The functional significance of ZAP-70 gene expression in this subgroup
of CLL B cells is unknown. ZAP-70 is a PTK that is characterized by 2 tandem src homology 2 (SH2) domains and a C-terminal catalytic
domain.7,8 Following ligation of the T cell receptor (TCR), there is activation of src family PTK that in turn
phosphorylates tyrosine-containing immunoreceptor tyrosine-based
activation motifs (ITAMs) within the cytoplasmic tails of the accessory
molecules of the TCR.9 ZAP-70 is recruited to the
phosphorylated ITAMs and subsequently becomes activated, in turn
causing activation of Tec family PTKs and downstream signaling
pathways, such as the phospholipase C Prior studies indicated that ZAP-70 could reconstitute BCR signaling in
Syk-deficient B cells.13 In addition, Syk apparently could
effect TCR signaling in patients deficient in ZAP-70.14 However, it is not known whether ZAP-70 protein is expressed in CLL,
let alone capable of undergoing phosphorylation or association with the
CLL BCR complex upon surface immunoglobulin ligation.
In the present study, we examined purified CLL B cells for expression
of ZAP-70 protein and examined whether ZAP-70 could potentially play a
role in BCR signal transduction.
Cell isolation
Flow cytometry
CLL B cells were isolated to greater than 99% purity by flow cytometry by means of a FACS-Starplus (Becton Dickinson) (data not shown). For this, the isolated blood mononuclear cells were stained with fluorochrome-conjugated mAbs for CD19. CD19+ cells were isolated and then examined for purity by staining a test aliquot of cells with fluorochrome-conjugated mAbs specific for CD3, CD5, and CD56. Cell treatment and sample preparation Frozen CLL cells were grown overnight in complete RPMI-1640 medium supplemented with 10% fetal bovine serum followed by 2 to 3 hours of serum starvation before BCR stimulation. The viability of the cells for each preparation always exceeded 90%, as assessed by trypan-blue exclusion. The cells were adjusted to 1 × 107 cells per milliliter in isotonic 0.1 M phosphate-buffered saline (pH, 7.2). BCR ligation was performed with the use of biotinylated goat antihuman immunoglobulin M (IgM) F(ab')2 (Southern Biotechnology Associates, Birmingham, AL) at 10 µg/mL. We incubated this reagent with the leukemia cells for 10 minutes on ice and then added Avidin (Sigma, St Louis, MO) to a final concentration of 10 µg/mL. The cell mixture was incubated at 37°C for a defined number of minutes to effect BCR signaling. Preliminary time course studies that examined for increases in tyrosine phosphorylation after 1, 5, 10, 15, and 30 minutes at 37°C revealed optimal stimulation at 10 minutes (data not shown). Therefore, in all subsequent experiments, the anti-IgM/avidin-treated leukemia cells were incubated for 10 minutes at 37°C, placed on ice, and then immediately pelleted by centrifugation at 4°C. Cell pellets were lysed in 200 µL ice-cold 1% Nonidet P-40 (NP-40) lysis buffer (10 mM Tris-HCl [tris(hydroxymethyl)aminomethane]-Hcl], pH 7.4; 5 mM EDTA [ethylenediaminetetraacetic acid]; 150 mM NaCl; 0.1% sodium dodecyl sulfate [SDS]; 0.1% sodium deoxycholate; 10 mM NaF; 1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride [AEBSF]; 0.8 µM aprotinin; 20 µM leupeptin; 36 µM bestatin; 15 µM pepstatin; 14 µM leucylamido-(4-guanidino)butane [E-64]) for 20 minutes on ice. For coimmunoprecipitation experiments, 1% NP-40 lysis buffer (10 mM Tris-HCl, pH 7.4; 5 mM EDTA; 50 mM NaCl; 0.1% SDS; and 0.1% sodium deoxycholate) was used. Cell lysates were clarified by centrifugation at 20 000g for 15 minutes.VH gene analyses Total cellular RNA was isolated from 5 × 106 CLL B cells by means of RNeasy (Qiagen, Valencia, CA), per the manufacturer's instructions. First-strand cDNA was synthesized from one third of the total purified RNA by means of an oligodeoxythymidine (oligo-dT) primer and Superscript II RT (Life Technologies, Grand Island, NY). The remaining RNA was removed with RNase H, and the cDNA purified by means of QIAquik purification columns (Qiagen). The purified cDNA was poly-deoxyguanosine (poly-dG)-tailed by means of dG triphosphate (dGTP) and terminal deoxytransferase (Roche, Indianapolis, IN). The VH gene expressed by the CLL B cells was determined by reverse transcriptase-polymerase chain reaction (RT-PCR) enzyme-linked immunosorbent assay (ELISA) technique.17 The cDNA from each sample was amplified with the use of VH family-specific primers for the sense strand of the gene of interest and an antisense Cµ consensus oligonucleotide primer. The PCR products were size selected by electrophoresis in 2% agarose containing 0.5 µg/mL ethidium bromide (Life Technologies). The expected products were excised and purified by means of Geneclean III (BIO 101, Carlsbad, CA), per the manufacturer's instructions, and cloned into pGEM-T (Promega, Madison, WI). Following transformation of XL-1 Blue competent cells (Stratagene, La Jolla, CA), plasmid DNA was isolated from overnight cultures of randomly selected bacterial colonies by means of QIAprep purification columns (Qiagen). Sequencing was conducted by means of a fluorescence-dideoxy-chain-termination method and an Applied Biosystems 377 automated nucleic acid sequence analyzer (ABI, Foster City, CA). Nucleotide sequences were analyzed by means of DNASTAR (Madison, WI) and by comparison with sequences deposited in the V BASE and GenBank sequence databases. At least 3 independent clones were analyzed for each sample. Somatic mutations were identified by comparison with the most homologous germ line VH gene. The method of Corbett and colleagues18 was used to assign diversity (D) genes of the longer gene families (D2 and D3), and 7 consecutive nucleotides were used for the shorter D gene families.Immune precipitation and immunoblotting The protein concentration of each cell lysate was determined by means of the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA). First, 10 µg total cell lysate was loaded onto 10% SDS polyacrylamide gels for electrophoresis. The size-separated proteins were transferred to Immobilon-P (Millipore, Bedford, MA) transfer membranes. Membranes were blotted with primary antibody at 4°C overnight or at room temperature for 2 hours. For analysis of phosphotyrosine proteins, we used the phosphotyrosine-specific mAb 4G10 (Upstate Biotechnology, Lake Placid, NY). We incubated the blots with secondary antibodies that were conjugated with horseradish peroxidase for 1 hour at room temperature. Blots then were washed and prepared for enhanced chemiluminescence and subsequent autoradiography with Super RX film (Fuji, Tokyo, Japan). Defined sections of the film were scanned for density measurements by means of a Scanmaker IISP (Microtek, Carson, CA) and were analyzed with the use of National Institutes of Health (NIH; Bethesda, MD) Image software. To report the change in signal intensity following stimulation, we subtracted 1 from the ratio of signal intensity of the defined section for the stimulated sample over the signal intensity of the same sample before stimulation and multiplied this number by 100 to derive the percentage change in signal intensity.For immune precipitation studies, we incubated the lysates of 0.5 to 1 × 107 cells with saturating amounts of mouse mAbs specific for ZAP-70 (clone 29; Transduction Laboratories, Lexington, KY), CD79b (C-19; Santa Cruz Biotechnology, Santa Cruz, CA), or human IgM (Southern Biotechnology Associates), or affinity-purified rabbit antibodies to Syk (C-20; Santa Cruz Biotechnology). The lysates and antibodies were allowed to incubate either overnight at 4°C or for 2 hours at room temperature. Immune complexes were precipitated with 20 µL protein-A agarose beads (Pierce, Rockford, IL) for an additional 2-hour incubation at 4°C. The beads were washed twice with phosphate-buffered saline (PBS) and once with lysis buffer. Bound proteins were eluted by boiling the samples in SDS sample buffer and were then resolved by 10% SDS polyacrylamide gel electrophoresis.
ZAP-70 expression in CLL B cells We examined the leukemia B cells from 22 patients with CLL for expression of ZAP-70 protein. Twelve of the patients had CLL cells that expressed nonmutated immunoglobulin receptors, whereas the remainder had leukemia cells expressing immunoglobulin that had undergone somatic mutation (Figure 1).
A high proportion of cases expressed the VH1-69 gene that prior studies had identified as being expressed at high frequency in B-cell CLL.1,19 Two of the patients who had leukemia cells with mutated immunoglobulin V genes (CLL16 and CLL17) were monozygous twins who were concordant for CLL. Both twins were diagnosed at the age of 57 years after they incidentally were found to have a leukocytosis of approximately 12 000/mm3 on a routine clinical exam. However, one twin (CLL16) subsequently experienced progressive disease, a lymphocyte-doubling time of 2 years, and hyperlymphocytosis (greater than 285 000/mm3), whereas the other (CLL17) has had nonprogressive disease and maintains a stable total white blood cell count of no more than 17 500/mm3. Cell lysates were prepared from CLL cells isolated to greater than 99% purity by means of the fluorescence-activated cell sorter. ZAP-70 protein was detected by immunoblotting with anti-ZAP-70 mAb in
lysates of all 12 CLL cell samples that expressed nonmutated immunoglobulin V genes (Figure 2 and data
not shown). Moreover, the level of ZAP-70 protein detected in each of
the ZAP-70+ leukemia B-cell samples was comparable to that
found in isolated blood T cells from healthy adults (Figure
2). In contrast, CLL samples that expressed mutated immunoglobulin
receptors generally did not have ZAP-70 protein at levels exceeding
those found in control samples with 1% T cells (Figure 2). However,
all samples contained equivalent levels of
Of the 10 CLL samples that expressed mutated immunoglobulin receptors, we found that only 1 (CLL16) expressed high levels of ZAP-70 protein. Through primary sequence analyses, we deduced that the immunoglobulin heavy chain variable region of CLL16 had overall sequence homology of only 91.2% with the germ line sequences of the nearest fit, namely, immunoglobulin VH3-33, D6-6, and JH6 (Figure 1). Samples CLL16 and CLL17 were obtained from monozygotic twins who were concordant for CLL. Like CLL16, CLL17 also expressed mutated immunoglobulin genes with only 92% overall sequence homology with the germ line sequences of the nearest fit, namely, immunoglobulin VH3-15, D1-26, and JH4 (Figure 1). However, unlike CLL16, CLL17 did not have detectable levels of ZAP-70 protein (Figure 2). We examined each leukemia cell sample for expression of CD38. Five of the 12 cases that used nonmutated immunoglobulin genes (CLL3, CLL5, CLL8, CLL9, and CLL11) had high-level expression of CD38 (average MFIR, 15 ± 8.6, with 76% ± 23% of the leukemia cells on average found to be CD38+), whereas only 1 of the 10 cases with mutated immunoglobulin genes (CLL16) expressed this surface molecule (MFIR, 2.3, with 37% of leukemia cells found to be CD38+). Therefore, a significantly higher proportion of the samples that used nonmutated immunoglobulin genes expressed CD38 (41%) than did samples with mutated immunoglobulin receptors (10%) (P < .05, Student t test). Furthermore, all samples found to express CD38 also had ZAP-70 protein, including CLL16. However, 7 of the 12 cases (59%) that used nonmutated immunoglobulin genes and that also expressed ZAP-70 protein had insignificant expression of CD38 (average MFIR, 1.2 ± 0.4, with an average of 6.5% ± 6.5% of the leukemia cells found to be CD38+). All 9 cases other than CLL16 that expressed mutated immunoglobulin genes also had negligible expression of CD38 (average MFIR, 1.0 ± 0.2, with an average 0.9% ± 0.7% of the leukemia cells found to be CD38+), including CLL17 obtained from the twin sibling of CLL16. Functional analyses of BCR signaling We examined whether ligation of the BCR could induce tyrosine phosphorylation of cytosolic proteins in the CLL cases examined for expression of ZAP-70. Each of the freshly thawed leukemia cell samples had comparable expression of surface IgM, allowing us to use anti-µ F(ab')2 (anti-µ) as an agonist to effect BCR signaling (data not shown). We found that ligation of the BCR on CLL cell samples that expressed ZAP-70 (n = 13) induced tyrosine phosphorylation of many cytosolic proteins (Figure 3 and data not shown). This was observed even for CLL16, which expressed mutated immunoglobulin genes. Moreover, the increase in detected tyrosine phosphorylation following BCR ligation appeared greater in CLL cells that expressed ZAP-70 than in CLL cells that did not express ZAP-70 (Figure 3, and data not shown). In fact, ligation of the BCR on 8 of the CLL cell samples that did not express ZAP-70, including CLL17, did not induce any apparent changes in tyrosine phosphorylation, as detected by the antiphosphotyrosine antibody 4G10 (Figures 3 and 4, and data not shown).
To evaluate the relative increase in tyrosine phosphorylation, we measured the changes in density of bands identified on the immunoblot after BCR ligation. For example, signal intensity measurements of a defined area that included proteins of 70 to 72 kDa on the immunoblot allowed us to compare the relative increase in the density of the bands following BCR ligation (Figure 4). Following BCR ligation, the 13 cases that expressed ZAP-70 had an average 190% increase (± 120%) in band intensity. This was significantly greater than the 30% increase (± 30%) in band intensity observed for the 9 cases that did not express ZAP-70 protein (P < .01, Student t test; Figure 4, left panel). Expression of ZAP-70 also appeared more relevant than expression of
CD38 in defining the cases that responded to BCR ligation. The CLL cell
samples that expressed CD38 (n = 6) had on average a 220% increase
(± 140%) in the intensity of bands in this area following BCR
ligation. Linear regression analysis of the increase in band
intensities relative to the CD38 MFIR for each of these 6 CD38+ cases did not reveal a significant relationship,
providing a squared Pearson product-moment correlation coefficient
(R2) of only 0.4661 (data not shown). Although
the average increase in band intensity for these 6 CD38+
cases was significantly greater than the 30% average increase (± 30%) noted for the 9 CLL cell samples that expressed
neither CD38 nor ZAP-70 (P < .05, Bonferroni t
test), it was not significantly greater than the 170% average increase
(± 110%) noted for the 7 CD38 We examined samples for BCR-induced increases in tyrosine
phosphorylation of proteins of this size, namely p72Syk.
For this, we performed Syk immune precipitation of leukemia cell
lysates with anti-Syk antibodies before and after BCR ligation and then
probed the immunoblot with the antiphosphotyrosine antibody 4G10
(Figure 5A). Following BCR ligation, we
noted an average 180% increase (± 40%) in the band intensity of
P-Tyr Syk in the 5 examined cases that expressed ZAP-70. This
fold-ncrease was significantly greater than that induced in the 5 examined leukemia cells that did not express ZAP-70
(m = 40% ± 20%) (P < .05, Student t
test). Stripping the blots and then reprobing them for Syk revealed that all of the 10 studied cases had similar amounts of Syk
protein (Figure 5A, bottom panel).
Similarly, we prepared immune precipitates from lysates of ZAP-70+ leukemia cases before and after BCR ligation using antibodies to ZAP-70. Immunoblot analyses of these samples with antiphosphotyrosine antibodies revealed that the signal intensity of ZAP-70 increased following anti-µ stimulation (Figure 5B). ZAP-70 protein was found in each lane when the blots were stripped and then reprobed with anti-ZAP-70 antibody (Figure 5B, bottom panel). That ZAP-70 undergoes tyrosine phosphorylation within minutes of BCR
ligation suggests that ZAP-70 may associate with the surface BCR
complex. To examine for this, we prepared immune precipitates with
antihuman IgM (Figure 6A) or anti-CD79b
(Figure 6B) from ZAP-70+ cases before and after anti-µ
stimulation. Immunoblot analyses with ZAP-70 antibodies revealed ZAP-70
in lanes with lysates prepared from anti-µ-stimulated cases. There
was little or no detectable ZAP-70 signal in the samples prior
to BCR ligation. In contrast, both prestimulated and poststimulated
samples contained similar levels of µ (Figure 6A) or CD79b protein
(Figure 6B), indicating that all immune precipitates had captured
similar levels of target protein.
In this study, CLL B cells that expressed nonmutated immunoglobulin V genes were found to express levels of ZAP-70 protein that were comparable to those detected in blood T cells of healthy adults. In contrast, leukemia cells that expressed mutated immunoglobulin receptors generally did not express detectable levels of ZAP-70 protein. These results agree with those obtained with the use of microarray to assess the gene-expression profiles of CLL B cells.5 However, in this study, we found that the association between the use of nonmutated immunoglobulin genes and the expression of ZAP-70 was not absolute, in that one of the CLL samples that expressed mutated immunoglobulin receptors also expressed high levels of the T-cell receptor PTK. Nevertheless, we note that a significantly higher proportion of the 12 cases with nonmutated immunoglobulin genes expressed ZAP-70 (100%) than did the 10 cases with mutated immunoglobulin receptors (10%) (P < .01). High-level expression of CD38 correlated with expression of ZAP-70. CD38 is a 45-kDa type II transmembrane glycoprotein with ectoenzymatic activity,20-22 which has been argued to play a complex role in B-cell activation and proliferation.23 CLL-cell expression of CD38 has been associated with the use of nonmutated immunoglobulin V genes and more aggressive clinical disease.2,24 However, similar to other studies,25 we found that the expression of CD38 was not invariably associated with immunoglobulin mutational status. Indeed, one of the samples that expressed mutated immunoglobulin V genes (CLL16) also expressed CD38. Because this case also was ZAP-70+, it is conceivable that CD38 may play a role in expression of ZAP-70. However, because 7 of the 13 CLL cases that were ZAP-70+ had only negligible levels of CD38, expression of ZAP-70 appears neither dependent on CD38 nor sufficient to induce its expression in CLL. The use of samples obtained from monozygotic twins concordant for CLL allowed us to examine for differences in leukemia cell populations that are likely due to somatic events. The CLL cells from both twins expressed mutated immunoglobulin VH genes of the VH3 subgroup, but were discordant for expression of ZAP-70 and CD38. Because these twins were monozygous, this analysis suggests that the differences between patients in leukemia-cell expression of ZAP-70 and/or CD38 in CLL cannot be explained by genetic polymorphism. We found that leukemia cell samples that expressed ZAP-70 had a greater increase in tyrosine phosphorylation following BCR ligation than did leukemia cell samples lacking expression of ZAP-70. Prior studies demonstrated that CLL cases were heterogeneous in their ability to respond to BCR cross-linking.26,27 Furthermore, CLL cells that expressed CD38 appeared more responsive to BCR ligation.28 This association between CD38 and signaling intensity was also observed in the leukemia cell samples examined in this study. However, this may just be a reflection of the noted association between CD38 and expression of ZAP-70. All cases that expressed ZAP-70 were noted to have an increase in tyrosine phosphorylation following BCR ligation. Moreover, the extent of the average BCR-induced increase in signal intensity for ZAP-70 cases, even for ZAP-70+ cases that had negligible expression of CD38 (Figure 4), was significantly higher than that noted for samples that did not express ZAP-70. One of the proteins that is phosphorylated after BCR ligation is Syk. Syk is an important PTK in the BCR-signaling pathway.12,29,30 Prior studies noted that the CLL cells of different patients varied in the extent to which Syk was phosphorylated following BCR ligation.31,32 Moreover, the extent to which Syk underwent tyrosine phosphorylation appeared to be associated with the ability of the leukemia cells to respond to BCR ligation.32 However, as noted in this and a prior study,32 the differences between CLL cases in the levels of Syk phosphorylation following BCR ligation were not apparently related to differences in the levels of Syk protein found in each of the CLL cell populations. Instead, we found that the leukemia cells that were better able to respond to BCR ligation expressed ZAP-70 in addition to Syk. Moreover, the average level of BCR-induced Syk phosphorylation in such cases was significantly greater than that observed in cases that did not express ZAP-70. It is not clear whether expression of ZAP-70 contributes to the enhanced BCR-signaling capacity noted for CLL samples that express this protein. Prior studies indicated that Syk has an approximately 100-fold greater intrinsic PTK activity than does ZAP-70.33 Also, in contrast to ZAP-70, Syk can undergo stimulation in the absence of src-related kinases, initiate immunoreceptor signaling, and promote tyrosine phosphorylation of ITAMs in the BCR complex.34 In addition, normal B cells do not express ZAP-70 and yet respond to BCR ligation as well as do the CLL cases that have the highest response to stimulation via the BCR complex.32 Therefore, ZAP-70 is not necessary for effective BCR signaling, at least by normal B cells. Nevertheless, the association between expression of ZAP-70 and magnitude of tyrosine phosphorylation induced by surface immunoglobulin cross-linking in CLL suggests that this PTK may enhance the signaling capacity of the BCR complex in B-cell CLL. Consistent with this notion, we found evidence that ZAP-70 may function in BCR signaling. Following ligation of the BCR, we found that ZAP-70 undergoes tyrosine phosphorylation and complexes with the proteins of the BCR complex. Conceivably, expression of ZAP-70 may lower the threshold for BCR signaling. ZAP-70 has been reported to promote tyrosine phosphorylation of the T-cell-receptor signaling motifs in immature CD4+CD8+ thymocytes in response to TCR cross-linking.35 Therefore, ZAP-70 may function to enhance phosphorylation of such motifs in CLL B cells and thereby lower the threshold for Syk phosphorylation following BCR ligation. Alternatively, expression of ZAP-70 in CLL cells may enhance the stability of phosphorylated Syk, allowing accumulation of the functional form of Syk in CLL following BCR ligation. Transfection of leukemia cells that lack ZAP-70 may be required to test these hypotheses. Nevertheless, expression of ZAP-70 appears most closely associated with the relative capacity of the BCR complex to effect signaling in the CLL B cell. Such differences may contribute to the noted clinical heterogeneity among patients with this disease.
The authors appreciate the skilled advice and assistance of Ms Esther Avery.
Submitted June 16, 2002; accepted July 21, 2002.
Prepublished online as Blood First Edition Paper, August 8, 2002; DOI 10.1182/blood-2002-06-1683.
Supported in part by National Institutes of Health grants R37 CA49870 (T.J.K.) and PO1 CA81534 (CLL Research Consortium) and P01 AI45865 (A.W.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Thomas J. Kipps, 9500 Gilman Dr, UCSD School of Medicine, La Jolla, CA 92093; e-mail: tkipps{at}ucsd.edu.
1. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102:1515-1525[Medline] [Order article via Infotrieve].
2.
Damle RN, Wasil T, Fais F, et al.
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Blood.
1999;94:1840-1847
3.
Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK.
Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.
Blood.
1999;94:1848-1854
4.
Maloum K, Davi F, Merle-Beral H, et al.
Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia.
Blood.
2000;96:377-379
5.
Rosenwald A, Alizadeh AA, Widhopf G, et al.
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.
J Exp Med.
2001;194:1639-1647
6.
Klein U, Tu Y, Stolovitzky GA, et al.
Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells.
J Exp Med.
2001;194:1625-1638
7.
Taniguchi T, Kobayashi T, Kondo J, et al.
Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis.
J Biol Chem.
1991;266:15790-15796 8. Chan AC, Iwashima M, Turck CW, Weiss A. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell. 1992;71:649-662[CrossRef][Medline] [Order article via Infotrieve]. 9. Qian D, Weiss A. T cell antigen receptor signal transduction. Curr Opin Cell Biol. 1997;9:205-212[CrossRef][Medline] [Order article via Infotrieve]. 10. Kane LP, Lin J, Weiss A. Signal transduction by the TCR for antigen. Curr Opin Immunol. 2000;12:242-249[CrossRef][Medline] [Order article via Infotrieve]. 11. Chan AC, van Oers NS, Tran A, et al. Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. J Immunol. 1994;152:4758-4766[Abstract].
12.
Law CL, Sidorenko SP, Chandran KA, et al.
Molecular cloning of human Syk: a B cell protein-tyrosine kinase associated with the surface immunoglobulin M-B cell receptor complex.
J Biol Chem.
1994;269:12310-12319 13. Kong GH, Bu JY, Kurosaki T, Shaw AS, Chan AC. Reconstitution of Syk function by the ZAP-70 protein tyrosine kinase. Immunity. 1995;2:485-492[CrossRef][Medline] [Order article via Infotrieve]. 14. Toyabe S, Watanabe A, Harada W, Karasawa T, Uchiyama M. Specific immunoglobulin E responses in ZAP-70-deficient patients are mediated by Syk-dependent T-cell receptor signalling. Immunology. 2001;103:164-171[CrossRef][Medline] [Order article via Infotrieve]. 15. Kipps TJ. Chronic lymphocytic leukemia and related diseases. In Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, eds. Williams Hematology. 6th ed. New York: McGraw-Hill; 2001:1163-1194. 16. Kipps TJ. Flow cytometry. In: Beutler E,Lichtman MA,Coller BS,Kipps TJ, eds. Williams Hematology. 5th ed. New York: McGraw-Hill; 1995:L56-L62. 17. Rassenti LZ, Kohsaka H, Kipps TJ. Analysis of immunoglobulin VH gene repertoire by an anchored PCR-ELISA. Ann N Y Acad Sci. 1995;764:463-473[Medline] [Order article via Infotrieve]. 18. Corbett SJ, Tomlinson IM, Sonnhammer EL, Buck D, Winter G. Sequence of the human immunoglobulin diversity (D) segment locus: a systematic analysis provides no evidence for the use of DIR segments, inverted D segments, "minor" D segments or D-D recombination. J Mol Biol. 1997;270:587-597[CrossRef][Medline] [Order article via Infotrieve].
19.
Kipps TJ, Tomhave E, Pratt LF, et al.
Developmentally restricted VH gene expressed at high frequency in chronic lymphocytic leukemia.
Proc Natl Acad Sci U S A.
1989;86:5913-5917
20.
Howard M, Grimaldi JC, Bazan JF, et al.
Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38.
Science.
1993;262:1056-1059 21. Summerhill RJ, Jackson DG, Galione A. Human lymphocyte antigen CD38 catalyzes the production of cyclic ADP-ribose. FEBS Lett. 1993;335:231-233[CrossRef][Medline] [Order article via Infotrieve]. 22. Mehta K, Shahid U, Malavasi F. Human CD38, a cell-surface protein with multiple functions. FASEB J. 1996;10:1408-1417[Abstract]. 23. Lund FE, Yu N, Kim KM, Reth M, Howard MC. Signaling through CD38 augments B cell antigen receptor (BCR) responses and is dependent on BCR expression. J Immunol. 1996;157:1455-1467[Abstract]. 24. Jelinek DF, Tschumper RC, Geyer SM, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol. 2001;115:854-861[CrossRef][Medline] [Order article via Infotrieve].
25.
Hamblin TJ, Orchard JA, Gardiner A, et al.
Immunoglobulin V genes and CD38 expression in CLL.
Blood.
2000;95:2455-2457 26. Hivroz C, Grillot-Courvalin C, Brouet JC, Seligmann M. Heterogeneity of responsiveness of chronic lymphocytic leukemic B cells to B cell growth factor or interleukin 2. Eur J Immunol. 1986;16:1001-1004[Medline] [Order article via Infotrieve]. 27. Hivroz C, Grillot-Courvalin C, Labaume S, Miglierina R, Brouet JC. Cross-linking of membrane IgM on B CLL cells: dissociation between intracellular free Ca2+ mobilization and cell proliferation. Eur J Immunol. 1988;18:1811-1817[Medline] [Order article via Infotrieve].
28.
Zupo S, Isnardi L, Megna M, et al.
CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis.
Blood.
1996;88:1365-1374 29. DeFranco AL. Transmembrane signaling by antigen receptors of B and T lymphocytes. Curr Opin Cell Biol. 1995;7:163-175[CrossRef][Medline] [Order article via Infotrieve]. 30. Sefton BM, Taddie JA. Role of tyrosine kinases in lymphocyte activation. Curr Opin Immunol. 1994;6:372-379[CrossRef][Medline] [Order article via Infotrieve].
31.
Lankester AC, van Schijndel GM, van der Schoot CE, et al.
Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells.
Blood.
1995;86:1090-1097 32. Semichon M, Merle-Beral H, Lang V, Bismuth G. Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells. Leukemia. 1997;11:1921-1928[CrossRef][Medline] [Order article via Infotrieve].
33.
Latour S, Chow LM, Veillette A.
Differential intrinsic enzymatic activity of Syk and Zap-70 protein-tyrosine kinases.
J Biol Chem.
1996;271:22782-22790 34. Zoller KE, MacNeil IA, Brugge JS. Protein tyrosine kinases Syk and ZAP-70 display distinct requirements for Src family kinases in immune response receptor signal transduction. J Immunol. 1997;158:1650-1659[Abstract].
35.
Ashe JM, Wiest DL, Abe R, Singer A.
ZAP-70 protein promotes tyrosine phosphorylation of T cell receptor signaling motifs (ITAMs) in immature CD4(+)8(+) thymocytes with limiting p56(lck).
J Exp Med.
1999;189:1163-1168
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. P. Quiroga, K. Balakrishnan, A. V. Kurtova, M. Sivina, M. J. Keating, W. G. Wierda, V. Gandhi, and J. A. Burger B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406 Blood, July 30, 2009; 114(5): 1029 - 1037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Buchner, S. Fuchs, G. Prinz, D. Pfeifer, K. Bartholome, M. Burger, N. Chevalier, L. Vallat, J. Timmer, J. G. Gribben, et al. Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia Cancer Res., July 1, 2009; 69(13): 5424 - 5432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Yin, K. I-C. Lin, R. P. Ketterling, R. A. Knudson, L. J. Medeiros, L. L. Barron, Y. O. Huh, R. Luthra, M. J. Keating, and L. V. Abruzzo Chronic Lymphocytic Leukemia With t(2;14)(p16;q32) Involves the BCL11A and IgH Genes and Is Associated With Atypical Morphologic Features and Unmutated IgVH Genes Am J Clin Pathol, May 1, 2009; 131(5): 663 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Burger, M. P. Quiroga, E. Hartmann, A. Burkle, W. G. Wierda, M. J. Keating, and A. Rosenwald High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation Blood, March 26, 2009; 113(13): 3050 - 3058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. BOELENS, S. LUST, B. VANHOECKE, and F. OFFNER Chronic Lymphocytic Leukaemia Anticancer Res, February 1, 2009; 29(2): 605 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Kipps Chronic Lymphocytic Leukemia: Advances in Assessing Prognosis and Therapy ASCO Educational Book, January 1, 2009; 2009(1): 385 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bekeredjian-Ding, A. Doster, M. Schiller, P. Heyder, H.-M. Lorenz, B. Schraven, U. Bommhardt, and K. Heeg TLR9-Activating DNA Up-Regulates ZAP70 via Sustained PKB Induction in IgM+ B Cells J. Immunol., December 15, 2008; 181(12): 8267 - 8277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Z. Rassenti, S. Jain, M. J. Keating, W. G. Wierda, M. R. Grever, J. C. Byrd, N. E. Kay, J. R. Brown, J. G. Gribben, D. S. Neuberg, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia Blood, September 1, 2008; 112(5): 1923 - 1930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Guarini, S. Chiaretti, S. Tavolaro, R. Maggio, N. Peragine, F. Citarella, M. R. Ricciardi, S. Santangelo, M. Marinelli, M. S. De Propris, et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells Blood, August 1, 2008; 112(3): 782 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Malavasi, S. Deaglio, A. Funaro, E. Ferrero, A. L. Horenstein, E. Ortolan, T. Vaisitti, and S. Aydin Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology Physiol Rev, July 1, 2008; 88(3): 841 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Muzio, B. Apollonio, C. Scielzo, M. Frenquelli, I. Vandoni, V. Boussiotis, F. Caligaris-Cappio, and P. Ghia Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy Blood, July 1, 2008; 112(1): 188 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Ghia, S. Jain, G. F. Widhopf II, L. Z. Rassenti, M. J. Keating, W. G. Wierda, J. G. Gribben, J. R. Brown, K. R. Rai, J. C. Byrd, et al. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection Blood, May 15, 2008; 111(10): 5101 - 5108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. F. Widhopf II, C. J. Goldberg, T. L. Toy, L. Z. Rassenti, W. G. Wierda, J. C. Byrd, M. J. Keating, J. G. Gribben, K. R. Rai, and T. J. Kipps Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3 Blood, March 15, 2008; 111(6): 3137 - 3144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Cutrona, M. Colombo, S. Matis, M. Fabbi, M. Spriano, V. Callea, E. Vigna, M. Gentile, S. Zupo, N. Chiorazzi, et al. Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells Haematologica, March 1, 2008; 93(3): 413 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Montel-Hagen, R. Vicente, and N. Taylor Unveiling ZAP-70's plan B Blood, March 1, 2008; 111(5): 2501 - 2502. [Full Text] [PDF]
|
|
|
|
|
|
L. Chen, L. Huynh, J. Apgar, L. Tang, L. Rassenti, A. Weiss, and T. J. Kipps ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia Blood, March 1, 2008; 111(5): 2685 - 2692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Longo, L. Laurenti, S. Gobessi, S. Sica, G. Leone, and D. G. Efremov The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells Blood, January 15, 2008; 111(2): 846 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Hauswirth and U. Jager Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia Haematologica, January 1, 2008; 93(1): 14 - 19. [Full Text] [PDF]
|
|
|
|
|
|
T. J. Kipps Chronic Lymphocytic Leukemia: Prognostic Markers and Revised Criteria for Treatment and Response Assessment ASCO Educational Book, January 1, 2008; 2008(1): 286 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Deaglio, T. Vaisitti, S. Aydin, L. Bergui, G. D'Arena, L. Bonello, P. Omede, M. Scatolini, O. Jaksic, G. Chiorino, et al. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential Blood, December 1, 2007; 110(12): 4012 - 4021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Damle, S. Temburni, C. Calissano, S. Yancopoulos, T. Banapour, C. Sison, S. L. Allen, K. R. Rai, and N. Chiorazzi CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells Blood, November 1, 2007; 110(9): 3352 - 3359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Willimott, M. Baou, S. Huf, S. Deaglio, and S. D. Wagner Regulation of CD38 in proliferating chronic lymphocytic leukemia cells stimulated with CD154 and interleukin-4 Haematologica, October 1, 2007; 92(10): 1359 - 1366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ian Mockridge, K. N. Potter, I. Wheatley, L. A. Neville, G. Packham, and F. K. Stevenson Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status Blood, May 15, 2007; 109(10): 4424 - 4431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Vallat, Y. Park, C. Li, and J. G. Gribben Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells Blood, May 1, 2007; 109(9): 3989 - 3997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gobessi, L. Laurenti, P. G. Longo, S. Sica, G. Leone, and D. G. Efremov ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells Blood, March 1, 2007; 109(5): 2032 - 2039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Abrams, T. Lakum, K. Lin, G. M. Jones, A. T. Treweeke, M. Farahani, M. Hughes, M. Zuzel, and J. R. Slupsky B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase C{beta}II Blood, February 1, 2007; 109(3): 1193 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Tinhofer, G. Rubenzer, C. Holler, E. Hofstaetter, M. Stoecher, A. Egle, M. Steurer, and R. Greil Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia Blood, November 1, 2006; 108(9): 2950 - 2956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Shanafelt, J. C. Byrd, T. G. Call, C. S. Zent, and N. E. Kay Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med, September 19, 2006; 145(6): 435 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Deaglio, T. Vaisitti, S. Aydin, E. Ferrero, and F. Malavasi In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia Blood, August 15, 2006; 108(4): 1135 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lin, M. A. Glenn, R. J. Harris, A. D. Duckworth, S. Dennett, J. C. Cawley, M. Zuzel, and J. R. Slupsky c-Abl Expression in Chronic Lymphocytic Leukemia Cells: Clinical and Therapeutic Implications. Cancer Res., August 1, 2006; 66(15): 7801 - 7809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Del Principe, G. Del Poeta, F. Buccisano, L. Maurillo, A. Venditti, A. Zucchetto, R. Marini, P. Niscola, M. A. I. Consalvo, C. Mazzone, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia Blood, August 1, 2006; 108(3): 853 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-A. Deglesne, N. Chevallier, R. Letestu, F. Baran-Marszak, T. Beitar, C. Salanoubat, L. Sanhes, J. Nataf, C. Roger, N. Varin-Blank, et al. Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of zap70 expression. Cancer Res., July 15, 2006; 66(14): 7158 - 7166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Richardson, C. Matthews, M. A. Catherwood, H. D. Alexander, B. S. Carey, J. Farrugia, A. Gardiner, S. Mould, D. Oscier, J. A. Copplestone, et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL) Blood, May 1, 2006; 107(9): 3584 - 3592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. H. Khan, S. Mendoza, P. Rhyne, M. Ziman, J. Tuscano, D. Eisinger, H.-J. Kung, and P. A. Luciw Multiplex Analysis of Intracellular Signaling Pathways in Lymphoid Cells by Microbead Suspension Arrays Mol. Cell. Proteomics, April 1, 2006; 5(4): 758 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kienle, A. Benner, A. Krober, D. Winkler, D. Mertens, A. Buhler, T. Seiler, U. Jager, P. Lichter, H. Dohner, et al. Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes Blood, March 1, 2006; 107(5): 2090 - 2093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Krober, J. Bloehdorn, S. Hafner, A. Buhler, T. Seiler, D. Kienle, D. Winkler, M. Bangerter, R. F. Schlenk, A. Benner, et al. Additional Genetic High-Risk Features Such As 11q Deletion, 17p Deletion, and V3-21 Usage Characterize Discordance of ZAP-70 and VH Mutation Status in Chronic Lymphocytic Leukemia J. Clin. Oncol., February 20, 2006; 24(6): 969 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Crespo, N. Villamor, E. Gine, A. Muntanola, D. Colomer, T. Marafioti, M. Jones, M. Camos, E. Campo, E. Montserrat, et al. ZAP-70 Expression in Normal Pro/Pre B Cells, Mature B Cells, and in B-Cell Acute Lymphoblastic Leukemia Clin. Cancer Res., February 1, 2006; 12(3): 726 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chiaretti, A. Guarini, M. S. De Propris, S. Tavolaro, S. Intoppa, A. Vitale, S. Iacobelli, L. Elia, C. Ariola, J. Ritz, et al. ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications Blood, January 1, 2006; 107(1): 197 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Allsup, A. S. Kamiguti, K. Lin, P. D. Sherrington, Z. Matrai, J. R. Slupsky, J. C. Cawley, and M. Zuzel B-Cell Receptor Translocation to Lipid Rafts and Associated Signaling Differ between Prognostically Important Subgroups of Chronic Lymphocytic Leukemia Cancer Res., August 15, 2005; 65(16): 7328 - 7337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. V. Abruzzo, J. Wang, M. Kapoor, L. J. Medeiros, M. J. Keating, W. E. Highsmith, L. L. Barron, C. C. Cromwell, and K. R. Coombes Biological Validation of Differentially Expressed Genes in Chronic Lymphocytic Leukemia Identified by Applying Multiple Statistical Methods to Oligonucleotide Microarrays J. Mol. Diagn., August 1, 2005; 7(3): 337 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Oppezzo, Y. Vasconcelos, C. Settegrana, D. Jeannel, F. Vuillier, M. Legarff-Tavernier, E. Y. Kimura, S. Bechet, G. Dumas, M. Brissard, et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia Blood, July 15, 2005; 106(2): 650 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Falt, M. Merup, G. Tobin, U. Thunberg, G. Gahrton, R. Rosenquist, and A. Wennborg Distinctive gene expression pattern in VH3-21 utilizing B-cell chronic lymphocytic leukemia Blood, July 15, 2005; 106(2): 681 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Petlickovski, L. Laurenti, X. Li, S. Marietti, P. Chiusolo, S. Sica, G. Leone, and D. G. Efremov Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells Blood, June 15, 2005; 105(12): 4820 - 4827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Raval, D. M. Lucas, J. J. Matkovic, K. L. Bennett, S. Liyanarachchi, D. C. Young, L. Rassenti, T. J. Kipps, M. R. Grever, J. C. Byrd, et al. TWIST2 Demonstrates Differential Methylation in Immunoglobulin Variable Heavy Chain Mutated and Unmutated Chronic Lymphocytic Leukemia J. Clin. Oncol., June 10, 2005; 23(17): 3877 - 3885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Kienle, C. Korz, B. Hosch, A. Benner, D. Mertens, A. Habermann, A. Krober, U. Jager, P. Lichter, H. Dohner, et al. Evidence for Distinct Pathomechanisms in Genetic Subgroups of Chronic Lymphocytic Leukemia Revealed by Quantitative Expression Analysis of Cell Cycle, Activation, and Apoptosis-Associated Genes J. Clin. Oncol., June 1, 2005; 23(16): 3780 - 3792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nedellec, Y. Renaudineau, A. Bordron, C. Berthou, N. Porakishvili, P. M. Lydyard, J.-O. Pers, and P. Youinou B Cell Response to Surface IgM Cross-Linking Identifies Different Prognostic Groups of B-Chronic Lymphocytic Leukemia Patients J. Immunol., March 15, 2005; 174(6): 3749 - 3756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Chen, J. Apgar, L. Huynh, F. Dicker, T. Giago-McGahan, L. Rassenti, A. Weiss, and T. J. Kipps ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia Blood, March 1, 2005; 105(5): 2036 - 2041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Chiorazzi, K. R. Rai, and M. Ferrarini Chronic Lymphocytic Leukemia N. Engl. J. Med., February 24, 2005; 352(8): 804 - 815. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fukuda, T. L. Toy, L. Z. Rassenti, K. R. Rai, and T. J. Kipps ICOS Is Induced by B Cell Receptor Signalling on Chronic Lymphocytic Leukemia B Cells. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 969 - 969. [Abstract]
|
|
|
|
|
|
A. Rodriguez, N. Martinez, F. I. Camacho, E. Ruiz-Ballesteros, P. Algara, J.-F. Garcia, J. Menarguez, T. Alvaro, M. F. Fresno, F. Solano, et al. Variability in the Degree of Expression of Phosphorylated I{kappa}B{alpha} in Chronic Lymphocytic Leukemia Cases With Nodal Involvement Clin. Cancer Res., October 15, 2004; 10(20): 6796 - 6806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. F. Widhopf II, L. Z. Rassenti, T. L. Toy, J. G. Gribben, W. G. Wierda, and T. J. Kipps Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins Blood, October 15, 2004; 104(8): 2499 - 2504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Jin, S. Pluskey, E. C. Petrella, S. M. Cantin, J. C. Gorga, M. J. Rynkiewicz, P. Pandey, J. E. Strickler, R. E. Babine, D. T. Weaver, et al. The Three-dimensional Structure of the ZAP-70 Kinase Domain in Complex with Staurosporine: IMPLICATIONS FOR THE DESIGN OF SELECTIVE INHIBITORS J. Biol. Chem., October 8, 2004; 279(41): 42818 - 42825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Z. Rassenti, L. Huynh, T. L. Toy, L. Chen, M. J. Keating, J. G. Gribben, D. S. Neuberg, I. W. Flinn, K. R. Rai, J. C. Byrd, et al. ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia N. Engl. J. Med., August 26, 2004; 351(9): 893 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Steinberg, O. Adjali, L. Swainson, P. Merida, V. D. Bartolo, L. Pelletier, N. Taylor, and N. Noraz T-cell receptor-induced phosphorylation of the {zeta} chain is efficiently promoted by ZAP-70 but not Syk Blood, August 1, 2004; 104(3): 760 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. K. Stevenson and F. Caligaris-Cappio Chronic lymphocytic leukemia: revelations from the B-cell receptor Blood, June 15, 2004; 103(12): 4389 - 4395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Rush, A. Raval, P. Funchain, A. J. Johnson, L. Smith, D. M. Lucas, M. Bembea, T.-H. Liu, N. A. Heerema, L. Rassenti, et al. Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets Cancer Res., April 1, 2004; 64(7): 2424 - 2433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Lu, Y. Zhao, R. Tawatao, H. B. Cottam, M. Sen, L. M. Leoni, T. J. Kipps, M. Corr, and D. A. Carson Activation of the Wnt signaling pathway in chronic lymphocytic leukemia PNAS, March 2, 2004; 101(9): 3118 - 3123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Mone, P. Huang, H. Pelicano, C. M. Cheney, J. M. Green, J. Y. Tso, A. J. Johnson, S. Jefferson, T. S. Lin, and J. C. Byrd Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells Blood, March 1, 2004; 103(5): 1846 - 1854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Jones, E. Addison, J. M. North, M. W. Lowdell, A. V. Hoffbrand, A. B. Mehta, K. Ganeshaguru, N. I. Folarin, and R. G. Wickremasinghe Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs Blood, March 1, 2004; 103(5): 1855 - 1861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Shanafelt, S. M. Geyer, and N. E. Kay Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL Blood, February 15, 2004; 103(4): 1202 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhong, C.-H. Wu, W.-H. Lee, and C.-P. Liu {zeta}-Associated Protein of 70 kDa (ZAP-70), but Not Syk, Tyrosine Kinase Can Mediate Apoptosis of T Cells through the Fas/Fas Ligand, Caspase-8 and Caspase-3 Pathways J. Immunol., February 1, 2004; 172(3): 1472 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Damle, F. M. Batliwalla, F. Ghiotto, A. Valetto, E. Albesiano, C. Sison, S. L. Allen, J. Kolitz, V. P. Vinciguerra, P. Kudalkar, et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations Blood, January 15, 2004; 103(2): 375 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kienle, A. Krober, T. Katzenberger, G. Ott, E. Leupolt, T. F. E. Barth, P. Moller, A. Benner, A. Habermann, H. K. Muller-Hermelink, et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome Blood, October 15, 2003; 102(8): 3003 - 3009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Wiestner, A. Rosenwald, T. S. Barry, G. Wright, R. E. Davis, S. E. Henrickson, H. Zhao, R. E. Ibbotson, J. A. Orchard, Z. Davis, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile Blood, June 15, 2003; 101(12): 4944 - 4951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Crespo, F. Bosch, N. Villamor, B. Bellosillo, D. Colomer, M. Rozman, S. Marce, A. Lopez-Guillermo, E. Campo, and E. Montserrat ZAP-70 Expression as a Surrogate for Immunoglobulin-Variable-Region Mutations in Chronic Lymphocytic Leukemia N. Engl. J. Med., May 1, 2003; 348(18): 1764 - 1775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Rai and N. Chiorazzi Determining the Clinical Course and Outcome in Chronic Lymphocytic Leukemia N. Engl. J. Med., May 1, 2003; 348(18): 1797 - 1799. [Full Text] [PDF]
|
|
|
|
|
|
B. Mavromatis and B. D. Cheson Monoclonal Antibody Therapy of Chronic Lymphocytic Leukemia J. Clin. Oncol., May 1, 2003; 21(9): 1874 - 1881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Durig, H. Nuckel, A. Huttmann, E. Kruse, T. Holter, K. Halfmeyer, A. Fuhrer, R. Rudolph, N. Kalhori, A. Nusch, et al. Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia Blood, April 1, 2003; 101(7): 2748 - 2755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Keating, N. Chiorazzi, B. Messmer, R. N. Damle, S. L. Allen, K. R. Rai, M. Ferrarini, and T. J. Kipps Biology and Treatment of Chronic Lymphocytic Leukemia Hematology, January 1, 2003; 2003(1): 153 - 175. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
-chain
CD3-receptor-associated protein tyrosine kinase (PTK) of T
lymphocytes. In contrast to CLL cells that have mutated immunoglobulin
receptors, CLL cells that use nonmutated immunoglobulin V genes express
ZAP-70 RNA.
/Ca++ signaling
pathway and the Ras/mitogen activated protein kinase (MAPK)
pathway.
) and silent (*) mutations in the
complementarity determining regions (CDRs) and framework regions (FWs)
of each heavy chain are indicated. Listed on the left margin are the
designations for the heavy chain of each CLL sample. Indicated
on the right margin are the VH genes, known D segments, and
JH genes that have the highest homology with each
heavy-chain cDNA sequence.
-actin, indicating that
all lanes had similar levels of protein loaded onto the gel (Figure 
)
or after (+) BCR stimulation with anti-µ F(ab')2. Lysates
from ZAP-70+ cases CLL1 (1) and CLL2 (2) are compared with
those of CLL13 (13) and CLL14 (14) in the left panel. Lysates from
samples obtained from monozygous twins, CLL16 (16) and CLL17 (17), but
that were discordant for expression of ZAP-70, are provided in the
right panel. Molecular weight markers are indicated on the left and
right margins. The brackets define the areas between 70 and 72 kDa in
size that were scanned for density with NIH image software. The blots
were stripped and then probed with anti-
)
express ZAP-70, whereas the graph on the right segregates samples on
the basis of whether they expressed ZAP-70 and CD38
(ZAP-70+/CD38+, left group); ZAP-70 without
CD38 (ZAP-70+/CD38
